Volitionrx (VNRX) Common Equity (2011 - 2025)

Volitionrx's Common Equity history runs 12 years deep, the most recent figure standing at -$35.6 million for Q4 2025.

• Quarterly Common Equity fell 36.33% year-over-year to -$35.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$35.6 million (down 36.33% YoY) and the FY2025 annual result came in at -$35.6 million, down 36.33% from the prior year.
• Common Equity was -$35.6 million for Q4 2025 at Volitionrx, up from -$35.9 million in the prior quarter.
• Across five years, Common Equity topped out at $31.2 million in Q1 2021 and bottomed at -$35.9 million in Q3 2025.
• A 5-year average of -$6.0 million and a median of -$3.1 million in 2022 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2021 — Common Equity jumped 239.27% — and 2024, when it slumped 694.03%.
• Volitionrx's Common Equity stood at $17.7 million in 2021, then plunged by 117.64% to -$3.1 million in 2022, then sank by 178.62% to -$8.7 million in 2023, then tumbled by 199.67% to -$26.1 million in 2024, then plunged by 36.33% to -$35.6 million in 2025.
• Business Quant data shows VNRX's Common Equity at -$35.6 million in Q4 2025, -$35.9 million in Q3 2025, and -$33.1 million in Q2 2025.